Advances in diagnostic and treatment options in patients with fibromyalgia syndrome
Jill M Recla1,21IGERT Program in Functional Genomics, Graduate School of Biomedical Sciences, The University of Maine, Orono, ME, USA; 2The Jackson Laboratory, Bar Harbor, ME, USADear Dr Liu,I have read with great interest the article entitled “Advances in diagnostic and treatment opti...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/6bda0dea9e27469ab219c6198018a50a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:6bda0dea9e27469ab219c6198018a50a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:6bda0dea9e27469ab219c6198018a50a2021-12-02T05:33:38ZAdvances in diagnostic and treatment options in patients with fibromyalgia syndrome1179-156Xhttps://doaj.org/article/6bda0dea9e27469ab219c6198018a50a2010-06-01T00:00:00Zhttp://www.dovepress.com/letter-advances-in-diagnostic-and-treatment-options-in-patients-a4657https://doaj.org/toc/1179-156XJill M Recla1,21IGERT Program in Functional Genomics, Graduate School of Biomedical Sciences, The University of Maine, Orono, ME, USA; 2The Jackson Laboratory, Bar Harbor, ME, USADear Dr Liu,I have read with great interest the article entitled “Advances in diagnostic and treatment options in patients with fibromyalgia syndrome” by Gur and Oktayoglu, which has been published online in Open Access Rheumatology: Research and Reviews.1 The authors aimed to evaluate new diagnostic tools and new therapeutic treatment approaches for fibromyalgia (FM). I would like to comment on the article by referring to my recently published work in Medical Hypotheses,2 which the authors reference in their section on the N-methyl d-aspartate receptor (NMDAR) antagonist memantine. My article describes the hypothesis that a combined therapeutic approach of the pharmaceuticals pregabalin and memantine may provide analgesic and neuroprotective benefits to patients with FM. The authors’ statement, which directly references my work – “Memantine may also suppress neuronal excitability and confers neuroprotection in a manner similar to pregabalin” – was either misinterpreted or misquoted from my article, in which I make a similar statement (using the word “confer” rather than “confers”). Although the syntactical difference is slight, the ramifications are profound, and I thusly feel that this statement requires further clarification. Jill M ReclaDove Medical PressarticleDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol 2010, Iss default, Pp 27-28 (2010) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Diseases of the musculoskeletal system RC925-935 |
| spellingShingle |
Diseases of the musculoskeletal system RC925-935 Jill M Recla Advances in diagnostic and treatment options in patients with fibromyalgia syndrome |
| description |
Jill M Recla1,21IGERT Program in Functional Genomics, Graduate School of Biomedical Sciences, The University of Maine, Orono, ME, USA; 2The Jackson Laboratory, Bar Harbor, ME, USADear Dr Liu,I have read with great interest the article entitled “Advances in diagnostic and treatment options in patients with fibromyalgia syndrome” by Gur and Oktayoglu, which has been published online in Open Access Rheumatology: Research and Reviews.1 The authors aimed to evaluate new diagnostic tools and new therapeutic treatment approaches for fibromyalgia (FM). I would like to comment on the article by referring to my recently published work in Medical Hypotheses,2 which the authors reference in their section on the N-methyl d-aspartate receptor (NMDAR) antagonist memantine. My article describes the hypothesis that a combined therapeutic approach of the pharmaceuticals pregabalin and memantine may provide analgesic and neuroprotective benefits to patients with FM. The authors’ statement, which directly references my work – “Memantine may also suppress neuronal excitability and confers neuroprotection in a manner similar to pregabalin” – was either misinterpreted or misquoted from my article, in which I make a similar statement (using the word “confer” rather than “confers”). Although the syntactical difference is slight, the ramifications are profound, and I thusly feel that this statement requires further clarification. |
| format |
article |
| author |
Jill M Recla |
| author_facet |
Jill M Recla |
| author_sort |
Jill M Recla |
| title |
Advances in diagnostic and treatment options in patients with fibromyalgia syndrome |
| title_short |
Advances in diagnostic and treatment options in patients with fibromyalgia syndrome |
| title_full |
Advances in diagnostic and treatment options in patients with fibromyalgia syndrome |
| title_fullStr |
Advances in diagnostic and treatment options in patients with fibromyalgia syndrome |
| title_full_unstemmed |
Advances in diagnostic and treatment options in patients with fibromyalgia syndrome |
| title_sort |
advances in diagnostic and treatment options in patients with fibromyalgia syndrome |
| publisher |
Dove Medical Press |
| publishDate |
2010 |
| url |
https://doaj.org/article/6bda0dea9e27469ab219c6198018a50a |
| work_keys_str_mv |
AT jillmrecla advancesindiagnosticandtreatmentoptionsinpatientswithfibromyalgiasyndrome |
| _version_ |
1718400355821158400 |